Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension

被引:63
作者
Zhang, Le-Ning [1 ]
Vincelette, Jon [1 ]
Chen, Dawn [1 ]
Gless, Richard D. [1 ]
Anandan, Sampath-Kumar [1 ]
Rubanyi, Gabor M. [1 ]
Webb, Heather K. [1 ]
MacIntyre, D. Euan [1 ]
Wang, Yi-Xin [1 ]
机构
[1] Arete Therapeut Inc, San Francisco, CA 94080 USA
关键词
Epoxyeicosatrienoic acids; Soluble epoxide hydrolase; Endothelial dysfunction; Endothelial derived hyperpolarization factors; Cardiometabolic diseases; II-INDUCED HYPERTENSION; SMALL MESENTERIC-ARTERIES; NITRIC-OXIDE SYNTHASE; HYPERPOLARIZING FACTOR; OXIDATIVE STRESS; ZUCKER RATS; NADPH OXIDASE; HUMAN-BLOOD; PPAR-ALPHA; MICE;
D O I
10.1016/j.ejphar.2010.12.016
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Endothelial dysfunction is a hallmark of, and plays a pivotal role in the pathogenesis of cardiometabolic diseases, including type II diabetes, obesity, and hypertension. It has been well established that epoxyeicosatrienoic acids (EETs) act as an endothelial derived hyperpolarization factor (EDHF). Soluble epoxide hydrolase (s-EH) rapidly hydrolyses certain epoxylipids (e.g. EETs) to less bioactive diols (DHETs), thereby attenuating the evoked vasodilator effects. The aim of the present study was to examine if inhibition of s-EH can restore impaired endothelial function in three animal models of cardiometabolic diseases. Isolated vessel rings of the aorta and/or mesenteric artery from mice or rats were pre-contracted using phenylephrine or U46619. Endothelium-dependent and independent vasorelaxation to acetylcholine and sodium nitroprusside (SNP) were measured using wire myography in vessels isolated from db/db or diet-induced obesity (DIO) mice, and angiotensin II-induced hypertensive rats treated chronically with s-EH inhibitors AR9281 or AR9276 or with vehicle. Vasorelaxation to acetylcholine, but not to SNP was severely impaired in all three animal models. Oral administration of AR9281 or AR9276 abolished whole blood s-EH activity, elevated epoxy/diol lipid ratio, and abrogated endothelial dysfunction in all three models. Incubating the mesenteric artery of db/db mice with L-NAME and indomethacin to block nitric oxide (NO) and prostacyclin formation did not affect AR9821-induced improvement of endothelial function. These data indicate that inhibition of s-EH ameliorates endothelial dysfunction and that effects in the db/db model are independent of the presence of NO and cyclooxygenase derived prostanoids. Thus, preserving vasodilator EETs by inhibition of s-EH may be of therapeutic benefit by improving endothelial function in cardiometabolic diseases. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:68 / 74
页数:7
相关论文
共 42 条
  • [1] Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo
    Ai, Ding
    Fu, Yi
    Guo, Deliang
    Tanaka, Hiromasa
    Wang, Nanping
    Tang, Chaoshu
    Hammock, Bruce D.
    Shyy, John Y. -J.
    Zhu, Yi
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (21) : 9018 - 9023
  • [2] DIFFERENTIAL EFFECTS OF SUBSTRATE DEPLETION ON DRUG-INDUCED CONTRACTIONS OF RABBIT AORTA
    ALTURA, BM
    ALTURA, BT
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1970, 219 (06): : 1698 - +
  • [3] Crucial role of NO and endothelium-derived hyperpolarizing factor in human sustained conduit artery flow-mediated dilatation
    Bellien, Jeremy
    Iacob, Michele
    Gutierrez, Laurence
    Isabelle, Marc
    Lahary, Agnes
    Thuillez, Christian
    Joannides, Robinson
    [J]. HYPERTENSION, 2006, 48 (06) : 1088 - 1094
  • [4] Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors
    Campbell, William B.
    Falck, John R.
    [J]. HYPERTENSION, 2007, 49 (03) : 590 - 596
  • [5] Synergistic vascular protective effects of combined low doses of PPARα and PPARγ activators in angiotensin II-induced hypertension in rats
    De Ciuceis, C.
    Amiri, F.
    Iglarz, M.
    Cohn, J. S.
    Touyz, R. M.
    Schiffrin, E. L.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (01) : 45 - 53
  • [6] Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP
    Ding, H
    Howarth, AG
    Pannirselvam, M
    Anderson, TJ
    Severson, DL
    Wiehler, WB
    Triggle, CR
    Tuana, BS
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2005, 289 (01): : H206 - H211
  • [7] Impaired vascular function in small resistance arteries of LOX-1 overexpressing mice on high-fat diet
    Eichhorn, Birgit
    Muller, Gregor
    Leuner, Anja
    Sawamura, Tatsuya
    Ravens, Ursula
    Morawietz, Henning
    [J]. CARDIOVASCULAR RESEARCH, 2009, 82 (03) : 493 - 502
  • [8] Endothelial dysfunction: a comprehensive appraisal
    Esper, Ricardo J.
    Nordaby, Roberto A.
    Vilarino, Jorge O.
    Paragano, Antonio
    Cacharron, Jose L.
    Machado, Rogelio A.
    [J]. CARDIOVASCULAR DIABETOLOGY, 2006, 5 (1)
  • [9] Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels
    Fang, X
    Weintraub, NL
    McCaw, RB
    Hu, SM
    Harmon, SD
    Rice, JB
    Hammock, BD
    Spector, AA
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2004, 287 (06): : H2412 - H2420
  • [10] Endothelial dysfunction:: a multifaceted disorder
    Feletou, Michel
    Vanhoutte, Paul M.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 291 (03): : H985 - H1002